Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanitha Sekar

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Antiviral Therapy|August 24, 2007
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, Vanitha Sekar, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without foodThomas N Kakuda, Vanitha Sekar, Ludo Lavreys, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravirAnita A Mathias, John Hinkle, Gong Shen, et al.
Journal of Clinical Pharmacology|March 29, 2007
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteersVanitha Sekar, Dries Kestens, Sabrina Spinosa-Guzman, et al.
Journal of Hepatology|February 14, 2012
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label studyChristophe Moreno, Thomas Berg, Tawesak Tanwandee, et al.
British Journal of Clinical Pharmacology|July 6, 2007
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteersRichard M W Hoetelmans, Kris Mariën, Martine De Pauw, et al.
AIDS (London, England)|September 3, 2009
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescentsStéphane Blanche, Rosa Bologna, Pedro Cahn, et al.
AIDS (London, England)|June 3, 2009
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAnthony M Mills, Mark Nelson, Dushyantha Jayaweera, et al.
Antiviral Therapy|October 26, 2011
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trialMichael Manns, Henk Reesink, Thomas Berg, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2011
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trialsThomas N Kakuda, Samantha Abel, John Davis, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Antiviral Therapy|August 24, 2007
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteersMonika Schöller-Gyüre, Thomas N Kakuda, Vanitha Sekar, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without foodThomas N Kakuda, Vanitha Sekar, Ludo Lavreys, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravirAnita A Mathias, John Hinkle, Gong Shen, et al.
Journal of Clinical Pharmacology|March 29, 2007
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteersVanitha Sekar, Dries Kestens, Sabrina Spinosa-Guzman, et al.
Journal of Hepatology|February 14, 2012
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label studyChristophe Moreno, Thomas Berg, Tawesak Tanwandee, et al.
British Journal of Clinical Pharmacology|July 6, 2007
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteersRichard M W Hoetelmans, Kris Mariën, Martine De Pauw, et al.
AIDS (London, England)|September 3, 2009
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescentsStéphane Blanche, Rosa Bologna, Pedro Cahn, et al.
AIDS (London, England)|June 3, 2009
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAnthony M Mills, Mark Nelson, Dushyantha Jayaweera, et al.
Antiviral Therapy|October 26, 2011
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trialMichael Manns, Henk Reesink, Thomas Berg, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2011
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trialsThomas N Kakuda, Samantha Abel, John Davis, et al.
Pageof 3